Kyntra Bio, Inc.
NMS: KYNBLive Quote
📈 ZcoreAI Score
Our AI model analyzes Kyntra Bio, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get KYNB Z-Score →About Kyntra Bio, Inc.
Healthcare
Biotechnology
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
📊 Fundamental Analysis
Kyntra Bio, Inc. demonstrates exceptional profitability, with a profit margin of 2848.6%.
The company recently reported -59.3% revenue growth, which is negative, indicating a recent decline in revenue.
At a current price of $7.17, KYNB currently sits at the 30th percentile of its 52-week range (Range: $4.85 - $12.60).
🏥 Financial Health
✅
Profit Margin
Excellent
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$29.02M
Trailing P/E
--
Forward P/E
-0.70
Beta (5Y)
0.90
52W High
$12.60
52W Low
$4.85
Avg Volume
33K
Day High
Day Low